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Neuroinflammation, a specialized immune response that takes place in the central nervous system, has been linked to
neurodegenerative diseases, and specially, it has been considered as a hallmark of Alzheimer disease, the most common cause
of dementia in the elderly nowadays. Furthermore, neuroinflammation has been demonstrated to affect important processes in
the brain, such as the formation of new neurons, commonly known as adult neurogenesis. For this, many therapeutic approaches
have been developed in order to avoid or mitigate the deleterious effects caused by the chronic activation of the immune response.
Considering this, in this paper we revise the relationships between neuroinflammation, Alzheimer disease, and adult neurogenesis,
as well as the current therapeutic approaches that have been developed in the field.
1. Introduction
The inflammatory response is an early, specialized immune
reaction to tissue damage or pathogen invasion. In the central
nervous system (CNS), this process is known as neuroinflam-
mation and is characterized by the activation of the microglia
and astrocytes population [1–3], the increase in concentration
of different cytokines, and chemokines and, under certain
conditions, the disruption of the blood brain barrier and the
subsequent invasion of cells from the hematopoietic system to
the injury site [4]. Thus, the burden of protecting CNS from
injury falls on a specific group of cells: microglia, astrocytes,
and mast cells. Mast cells can be found within the brain
and their functions include the attractant and activation of
other immune cells by secreting proinflammatory cytokines,
and chemoattractants [5]. Astrocytes also contribute to
the immune response by liberating both pro- and anti-
inflammatory cytokines, chemokines and complement com-
ponents [6]. Finally, microglia (CNS-resident macrophages)
represent the main effector cells of the immune system in the
CNS. Under physiological conditions, they stay as a quiescent
population. In response to an infection or injury, they activate
acquiring a reactive inflammatory phenotype characterized
by an increased proliferation,morphological changes, and the
release of several inflammatory molecules such as cytokines,
reactive oxygen species, and nitric oxide [7].
Some aspects of the neuroinflammatory response result
beneficial for CNS outcomes. Among these benefits, neu-
roprotection phenomena, the maintenance of neurogenesis
as a mechanism of brain repair, the mobilization of neural
precursors for repair, remyelination, and even axonal regen-
eration are included [8, 9]. However, neuroinflammation
can be harmful too, leading to neuronal damage. Benefits
and detriments balance depends largely on the magnitude
of the immune response. In this sense, it is important to
distinguish between the two types of responses in which
inflammatory mechanism has traditionally been classified:
acute and chronic inflammation. The first one comprises the
immediate and early response to an injurious agent and is
basically a defensive response that paves the way for repair of
the damaged site being typically short-lived and unlikely to be
detrimental to long-term neuronal survival [10]. The chronic
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response occurswhen the harmful stimulus persists over time
and contrary to the acute form, it is a long-standing and
often self-perpetuating neuroinflammatory response which
in the end, results in detrimental consequences for neurons
[11]. Both acute and chronic responses have been related
with neurodegenerative disorders. Thus, stroke and injury
would associate with acute neuroinflammationwhile diseases
such as multiple sclerosis or Alzheimer disease (AD) would
be associated with the chronic form of the response. In
this scenario, another important process commonly related
with neurodegeneration and neuroinflammation emerges;
the formation of new neurons in the adulthood or adult
neurogenesis.
Adult neurogenesis occurs in mammals principally in
two brain regions: the subventricular zone (SVZ) and the
subgranular zone (SGZ) of the hippocampus. The neuronal
precursor cells (NPCs) that exist in both areas are a sub-
set of astrocytes that give rise to intermediate progenitors
which migrate and differentiate into new neurons of the
hippocampus (in SGZ neurogenesis) or the olfactory bulb (in
SVZ neurogenesis) [12]. Adult neurogenesis has been found
to be altered in several neurodegenerative disorders such
as Parkinson’s disease, Huntington’s disease, and AD (for a
review, see [13]). On the other hand, neuroinflammation is
a common feature of all these pathologies and, as it will be
commented in detail later, it has also a relevant influence on
adult neurogenesis.
Due to the interconnection among these processes, it is
important to consider them as a whole, taking into account
that alterations affecting any of them would probably have
consequences on the two others.
In this review, wewill summarize the role of neuroinflam-
mation in both adult neurogenesis and Alzheimer disease.
Related to this pathology, we will finally revise the recent
advances concerning therapeutic approaches with neuroin-
flammatory mechanisms as a main target.
2. Neuroinflammation and Adult Neurogenesis
It has been widely demonstrated that neuroinflammation
affects adult neurogenesis having both detrimental and bene-
ficial consequences which can result in enhancement and/or
inhibition of the process. The final result depends largely on
how microglia, macrophages, and/or astrocytes are activated
and the duration of the inflammation [14]. Furthermore, the
balance between the benefits and the detriments will have a
profound impact on the efficiency of brain repair [15], which
is of great importance in the context of the neurodegenerative
disorders.
It is known that microglia, as the first immunological
barrier against pathogens and environmental insults [16],
exert the aforementioned dual effects on adult neurogenesis,
resulting in pro or antineutogenic outcomes.
2.1. Proneurogenic Effects. An important study performed by
Sierra and colleagues demonstrated that resting microglia
play a crucial role in regulating the balance of newborn
neurons in the hippocampus thanks to their phagocytic
capacities [17]. Of the thousands of new cells born in the
SGZ of the dentate gyrus, only a part of them differentiate
and maturate into fully mature neurons. At least half of
these cells die, probably through apoptosis, within the first
few days to weeks after they are born [18–21]. Sierra et al.
[17] provided data that attributed to microglia the function
of removing those apoptotic new cells by phagocytosis.
Furthermore, they importantly proved that this action did not
require the activation of the microglial population. Recently,
it has been reported that not only microglia are essential
for adult neurogenesis but their functions and activity are
importantly regulated by neuronal progenitor cells too.Thus,
NPC-derived secreted factors are capable of modulating
microglia activation, proliferation, and phagocytosis [22].
This crosstalk persists during neuron lifetime, since adult
neurons are demonstrated to regulate microglia activation by
constitutively expression of several neuroimmunoregulatory
proteins such as CD200, CX
3
CL1 (or fractalkine), CD47,
CD55, or HMGB1 (for a review see [23]).
Further evidence of the proneurogenic effects of unchal-
lenged microglia comes from the work of Walton and col-
leagues. By in vitro studies they showed that this population
releases factors that rescue neuroblasts and instruct neuronal
cell differentiation [24].
However, not only resting microglia exert benefits on
adult neurogenesis. The acquisition of an active phenotype,
under certain conditions, can be beneficial too [16], thanks
to the liberation of anti-inflammatory cytokines with a broad
range of actions on neurogenesis. Among these, we can high-
light interleukin-4 and -10 (IL-4, IL-10) and transforming
growth factor-beta (TGF-𝛽). It is also important to keep in
mind that cytokines classically considered as proinflamma-
tory, such as interleukin-6 (IL-6), interleukin 1-𝛽 (IL-1𝛽),
and tumor necrosis factor-𝛼 (TNF-𝛼) can be involved in the
creation of a permissive environment for neurorepair too
[25], as several studies have demonstrated (see Table 1).
Finally, not only cytokines derived from microglia can
positively regulate neurogenesis. Other factors produced by
immune system cells which are involved in the neuroinflam-
matory response have been shown to have certain influence.
This is the case for granulocyte-macrophage colony stim-
ulating factor (GM-CSF) [26] and the granulocyte-colony
stimulating factor (G-CSF), with remarkable effects on the
differentiation of NSC in vitro [27] (Table 1).
2.2. Antineurogenic Effects. Neuroinflammation, although
beneficial as a physiological response to maintain brain
homeostasis, can have detrimental effects especially when it
turns out to be a chronic response. Activated miroglia release
proinflammatory cytokines which have been shown to affect
largely neurogenesis. The aforementioned IL-6, TNF-𝛼, and
IL-1𝛽 but also interleukin-1-alpha (IL-1𝛼), interleukin-18 (IL-
18) and interferon-𝛾 (IFN-𝛾) have detrimental consequences
for proliferation and/or differentiation of NSC (Table 1).
Among factors not released by microglia, CCL11 or eotaxin-
1, a small chemokine known by its implication in allergic
responses, has been recently linked to adult neurogenesis and
ageing [28]. When administered systemically to young mice,
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eotaxin is able to impair neurogenesis producing as a conse-
quence, learning and memory deficits [28]. Furthermore, it
seems to affect directly the number and size of neurospheres
formed from primary NPCs [28], suggesting that precursor
cells probably have receptors capable of binding the cytokine.
Finally, it is especially noteworthy to keep in mind that
most of the aforementioned factors are not only produced
by microglia, but for astrocytes too, which contribute to
the pathogenesis of neurodegenerative disorders as will be
commented later.
The effects of the abovementioned cytokines on neuroge-
nesis are summarized in Table 1.
3. Neuroinflammation and Alzheimer Disease
Neurodegenerative diseases are characterized by the progres-
sive loss of neurons from specific regions of the CNS, which is
believed to account for the cognitive and motor impairments
suffered by patients with these neurodegenerative disorders.
Importantly, inflammation is a process that has been closely
related to the onset of many of these diseases, such as Amy-
otrophic Lateral Syndrome (ALS), Multiple Sclerosis (MS),
Parkinsons Disease (PD) and Alzheimer Disease (AD) [29–
33]. Indeed, aberrant inflammatory responses are believed to
play a role in the etiology of these disorders.
At present, AD is the most common cause of dementia in
the elderly. It is estimated that 27 million people are affected
worldwide [34] and this number is expected to triple by 2050
due to the increase of the population life expectancy [35]. AD
is a neurodegenerative disorder which affects brain regions
that control memory and cognitive functions, which implies
that patients finally lose their memory and ability to learn, to
reason, to communicate and to carry out daily activities [36].
There are two different types of Alzheimer Disease, familiar
Alzheimer Disease (FAD) and Sporadic Alzheimer Disease
(SAD), and the origin of the disease could be different in
both familial and sporadic cases. In terms of FAD, mutations
in three different genes (presenilin-1 PS-1, presenilin 2 PS-2
and amyloid precursor protein APP) are likely to promote
the onset of the disease whereas for SAD, different risk
factors might be involved. Nevertheless, downstream the
initial causes of the disease some common factors may be
involved [37]. At a molecular level, AD is characterized
by the presence of two main hystopathological hallmarks:
senile plaques (extracellular aggregates composed by amyloid
peptide or A𝛽) and neurofibrillary tangles (intracellular
aggregates composed by hyperphosphorylated forms of tau
protein). A𝛽 results from the cleavage of APP and, although
it seems to have important developmental functions in cell
differentiation and possibly in the establishment of synapses
[38, 39], its functions in adult brain still remain unclear.
On the other hand, tau protein, the major component of
neurofibrillary tangles, is a microtubule associated protein
which contributes to the normal function of this intracellular
support structure. Under pathogenic conditions, tau is highly
phosphorylated reducing its ability to bind to microtubules
[40] and favoring the formation of protein aggregates.
As a part of the inflammatory response, gliosis is a
common feature of AD. Activated astrocytes and microglia
are characteristically found in abundance near neurons and
plaques. Besides, AD brains show increased expression of
several pro-inflammatory cytokines which are hardly found
in normal brains [61–64]. The main hypothesis proposes
the chronic inflammatory reaction as a response to the
accumulation ofA𝛽plaques and tangles [65]. Although initial
inflammatory response can be beneficial, chronic activation
of astrocytes andmicroglia has been shown to induce necrosis
in adjacent neurons by releasing reactive oxygen interme-
diates, nitric oxide, proteolytic enzymes, complementary
factors, or excitatory amino acids [66].
A𝛽 and their precursor APP are potent activators of glial
cells [67, 68]. Thus, A𝛽 binds to the microglial cell surface
regulating extracellular signal regulated kinase (ERK) and
mitogen-activated protein kinase (MAPK) pathways which
induces proinflammatory gene expression leading to cytokine
and chemokine production [69]. Several chemokines and
their receptors have been found to be upregulated in the
AD brain. For example, macrophage inflammatory protein
(MIP)-1𝛼 has been detected in reactive astrocytes nearby A𝛽
plaques [70]. In the same manner, changes in levels of many
cytokines have been described not only in AD brains but
also in blood and cerebrospinal fluid from patients. Thus,
increased levels of IL-1𝛼, IL-1𝛽, IL-6, TNF-𝛼, and GM-SF
have been reported in brain tissue [71, 72]. In serum from
patients, an increase in eotaxin, a cytokine recently linked
to adult neurogenesis and ageing has been also detected
[28] and, correlating to this, an increase in the expression
of its receptor, CCR3, has been found in AD brains, espe-
cially in microglia [73]. Importantly, several works describe
interactions between components of the senile plaques and
cytokines, which could be generating a positive feedback loop
for the neuroinflammatory process [74]. For example, A𝛽
protein is able to potentiate the secretion of IL-6 and IL-8
under several conditions [75]. Similarly, astrocytes might be
activated by A𝛽 [76], contributing to generating a proinflam-
matory environment via the liberation of several cytokines
and chemokines.
However, in some situations the role of microglia has
been shown to be beneficial, since the activation of this
population can decrease the accumulation of A𝛽 thanks to
their phagocytic ability which facilitates the clearance and
degradation of the aggregates [77]. Besides, microglia can
be beneficial too through the secretion of growth factors
such as the glia-derived neurotrophic factor (GDNF) which
favors neuron survival [78]. Similarly, a relatively unknown
cytokine, fractalkine, which has been demonstrated to have
important neuroprotective characteristics, has been recently
linked to the disease.Thus, fractalkine signaling (with its only
receptor CX
3
CR1) has been found to be altered in AD brains
in which reduced levels of the cytokine has been described
[79].
Finally, it is noteworthy to keep in mind that although
neurons have been traditionally believed to be passive
bystanders in neuroinflammation, they seem to contribute
to the production of neuroinflammatory molecules,
a phenomenon that could be relevant in AD. Thus, the
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Table 1: Effects of different cytokines on neurogenesis.
Cytokine Effects on neurogenesis References
IL-1𝛼 Increased astrocyte lineage [41]
IL-1𝛽
Stimulation of NPCs proliferation and differentiation
Decreased proliferation, survival, and neuronal differentiation
Increased astrocyte differentiation
[42]
[43]
[44]
IL-4 Increased oligodendrogenesis [45]
IL-6
Decreased proliferation, survival, and neuronal differentiation [46]
[47]
[48]
[49]
Differentiation of NSC to neuronal lineages
Increased neurogenesis
IL-10 Increased proliferation [50][51]
IL-18 Decreased survivalIncreased neuronal differentiation [52]
IFN-𝛾 Decreased proliferation and survival of multipotent progenitorsPromotion of differentiation and neurite outgrowth
[53]
[54]
[55]
CCL11 (eotaxin-1) Decreased Sox-2 progenitors, proliferation, and neuronal differentiation [28]
CX3CL1 (fractalkine) Decreased neurogenesis [56]
GM-CSF Stimulation of NPCs differentiation [57]
G-CSF Promotes NPCs differentiation [27]
TGF-𝛽 Decreased proliferationIncreased survival and neural differentiation
[58]
[59]
[60]
production of IL-1, IL-6, and TNF-𝛼 by neurons has
been reported. Indeed, these neuronal chemokines act as
messengers between neurons and glial cells (for a review, see
[80]).
As neuroinflammation represents an important hallmark
in AD and, as it has been shown in Section 2, it has a
remarkable influence on adult neurogenesis, modulating the
inflammatory environment could be beneficial not only for
improving the deficits directly provoked by the disease but
also for stimulating the endogenous ability of the brain
for repairing the damage. In this sense, it is important to
highlight that, especially in AD, understanding the role of
adult neurogenesis is of great importance considering that
one of the neurogenic zones is the hippocampus, structure
responsible for cognitive and learning capacities which is
largely affected in AD patients.
To date, it is not fully understood how adult neuro-
genesis is affected in neurodegenerative disorders. In AD,
contradictory results have been obtained from the study
of several animal models and the study of brain tissue by
biochemical and histological approaches. Different effects
on proliferation, differentiation, and survival have been
reported in AD transgenic animal models with mutations
in APP and tau or in both (for a review, see [81]). Besides,
alterations affecting NPCs and differentiation of newborn
neurons have been described in a glycogen-synthase kinase
3 overexpressing mouse model (GSK-3𝛽 has been proposed
as a key protein in AD [82]), with an important role of
microglia as a mediator of these damaging effects [83, 84]
among which, morphology alterations of newborn neurons
are included [85]. In humans, first datawere obtained byNagy
and colleagues in 1997 [86]. In this pioneer work, the authors
reported an increase in Ki-67 marker (staining proliferating
cells) in the hippocampus from AD patients. In 2004, Jin et
al. confirmed this result restricting it specifically to neurons
[87]. However, in 2006, another group, although reported an
increase in the proliferative status of presenileADbrains, they
demonstrated that these precursors finally differentiated into
glial cells [88].
Consequently, although adult neurogenesis remains an
unknown field to be further explored in Alzheimer disease,
it is likely to be affected in the disease. Taking into account
that this process is known to contribute to learning and
memory [89–91], an appropriate form to improve the subse-
quent deficits in cognitive functions associated to AD would
result from modulating factors, such as those implicated in
neuroinflammation, directly related to the correct formation
of the newborn neurons. Finally, we cannot forget that adult
neurogenesis declines with age, being a not so common event
in the elderly [92], a fact that reinforces evenmore the idea of
preserving or stimulating it as a brain repair mechanism.
4. Therapeutic Approaches
Based on the evidence that involves neuroinflammation
in the pathogenesis of Alzheimer disease, researchers
have focused their efforts on the development of anti-
inflammatory drugs as a treatment option for patients with
AD. Drugs such as the NSAIDs and glucocorticoid steroids
have been studied.
4.1. NSAIDs. NSAIDs is the abbreviation for “nonsteroidal
anti-inflammatory drugs.” They constitute a large family of
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compounds which includes the salicylate, propionic acid,
acetic acid, fenamate, oxicam, and the COX-2 inhibitor
classes (enzymes which regulate the homeostatic production
of prostanoids, implicated in the inflammatory response)
[36]. Epidemiological evidences indicate that NSAIDs may
lower the risk of developing AD [93–95], since patients
suffering from rheumatoid arthritis and osteoarthritis have
been shown to inversely correlate with the risk of develop
AD. Although beneficial effects have been observed both
in vitro and in vivo (for a review, see [80]), unfortunately,
clinical trials of NSAIDs in AD patients have not been very
fruitful [96], especially in the case of COX-2 inhibitors.
Thus, COX-2 inhibitor rofecoxib and the COX-1 and COX-
2 inhibitor naproxen, were unable to slow the progression
of the disease in patients with mild-moderate AD [97]. As
a possible hypothesis, it could be postulated that NSAIDs
might be useful to prevent the pathology but ineffective once
the disease occurs.
4.2. Glucocorticoid Steroids. These compounds are consid-
ered as potent anti-inflammatory agents that modulate the
transcription of several inflammatory molecules reducing,
for example, the expression of proinflammatory cytokines
and complement proteins [98]. However, the results obtained
in AD patients have not been very promising. Thus, the use
of some glucocorticoid steroids, such as prednisone, has not
revealed any benefit in terms of slowing cognitive decline
[99].
However, other therapies have been developed not
directly directed to reduce inflammation but to the main tar-
gets that induce the chronic activation of these mechanisms,
such as A𝛽 plaques or tau protein.
4.3. A𝛽-Based Immunization Strategies. the efficacy of these
therapies has been demonstrated in mouse models of the
disease. In 1999, Schenk and colleagues proved in an APP
mutant mice that A𝛽-directed vaccination prevented the
development of neuritic A𝛽 plaques reducing them in older
animals [100]. Furthermore, vaccination was effective in
reducing age-dependent learning deficits which correlated
with reductions in both soluble A𝛽 and tau [101]. Although
APPmodel does not recapitulate all common features of AD,
they resemble an early preclinical phase of the disease, which
may be the optimal phase to initiate a therapy for preventing
the disorder [102]. Importantly, efficacy of the vaccine was
also found in a nonhuman primate, the Caribbean vervet
[103]. Regarding the promising results obtained in animal
models, a clinical trial was launchedwithAN-1792 containing
preaggregated synthetic A𝛽
42
and the adjuvant QS-21 [104].
Although 6% of the patients developed meningoencephalitis,
some others developed A𝛽-antibody titres that correlated
with a slow cognitive decline [105], and this result encouraged
the development of several antibody fragments and human-
ized A𝛽-specific antibodies, which are currently in various
stages of clinical trials [102]. Time will tell whether these
therapies are effective enough to halt the disease.
4.4. Tau-Based Immunization Approaches. First approach
applying tau-based immunization was carried out by Rosen-
mann and colleagues in 2006 by injecting C57BL/6 wild-type
animals with full-recombinant human tau. The experiments
are unsuccessful since the vaccination caused encephalitis
[106]. Subsequently, other groups tried active immunization
approaches using tau phosphopeptides, obtaining promising
results in tau transgenic models, in which they were able to
prevent tau pathology in the absence of obvious side effects
(for a review, see [107]). However, one of the main problems
derived from these studies is the difficulty to translate
them into clinical practice. This is due to the fact that the
vaccinations were observed to prevent tau-related problems
when administered prior to the appearance of any pathology
or cognitive deficit, something that, nowadays, would be
impossible regarding the current diagnosis methods. At
present, the tau-targeted therapies that are in clinical trials
target tau phosphorylation by GSK-3, microtubule stability,
and aggregation [108].
Finally, it is important to highlight that considering
that A𝛽 pathology depends on the presence of tau [109,
110] and that A𝛽 deposition is absent in many tauopathies
(neurodegenerative diseases associated with the pathological
aggregation of tau), it is absolutely necessary to pursue a
tau-targeted treatment probably in combination with an A𝛽-
targeting approach.
5. Concluding Remarks
Although mechanisms underlaying Alzheimer disease
remain unclear, neuroinflammation seems to be a common
feature to neurodegenerative diseases with an important
contribution to the pathology, affecting among others,
physiological processes with a repairing function such as
the adult neurogenesis process. Thus, modulating neuroin-
flammation by targeting causing agents or/and trying to
ameliorate their harmful effects could be of great importance
to possibly, prevent ADpathology and contribute to stimulate
endogenous repairing mechanisms as the formation of new
neurons.
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